Zacks Investment Research upgraded shares of PHOTOMEDEX INC (PHMD) from NEUTRAL to OUTPERFORM on December 18, 2012, with a target price of $15.50.
Photomedex, Inc. develops, manufactures and markets therapeutic excimer laser-based instrumentation designed to treat psoriasis and vitiligo. They are also developing their technology for the treatment of other skin disorders. They've received the first Food and Drug Administration, or FDA, approval to market an excimer laser system, XTRAC system, for the treatment of psoriasis. They have commercially launched the XTRAC system in the United States.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on PHOTOMEDEX INC (PHMD),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment